login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
CHEMOMAB THERAPEUTICS LTD (CMMB) Stock News
USA
-
Nasdaq
- NASDAQ:CMMB -
US16385C2035
-
ADR
2.48
USD
+0.01 (+0.4%)
Last: 12/5/2025, 8:11:11 PM
2.52
USD
+0.04 (+1.61%)
After Hours:
12/5/2025, 8:11:11 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CMMB Latest News, Press Relases and Analysis
All
Press Releases
4 days ago - By: Chemomab Therapeutics Ltd.
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
4 days ago - By: Chemomab Therapeutics Ltd.
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
12 days ago - By: Chemomab Therapeutics Ltd.
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
16 days ago - By: Chemomab Therapeutics
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
a month ago - By: Zacks Investment Research
- Mentions:
GES
PARR
Best Momentum Stocks to Buy for Oct. 23
16 days ago - By: Chemomab Therapeutics
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
a month ago - By: Chemomab Therapeutics
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
a month ago - By: Chemomab Therapeutics
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
a month ago - By: Zacks Investment Research
- Mentions:
ALKS
AVDL
CSTL
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
2 months ago - By: Zacks Investment Research
- Mentions:
ANIP
ESPR
EVO
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
2 months ago - By: Zacks Investment Research
- Mentions:
ADCT
ZTS
ALLO
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
2 months ago - By: Zacks Investment Research
- Mentions:
SNY
TEVA
ALLO
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
2 months ago - By: Zacks Investment Research
- Mentions:
CDTX
ALLO
AKRO
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
4 months ago - By: Chemomab Therapeutics
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
4 months ago - By: Benzinga
- Mentions:
ACET
CLDX
ALC
BLRX
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
4 months ago - By: Chemomab Therapeutics
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
4 months ago - By: Chemomab Therapeutics
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
5 months ago - By: Chemomab Therapeutics
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
5 months ago - By: Chemomab Therapeutics
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
6 months ago - By: Chemomab Therapeutics
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
6 months ago - By: Chemomab Therapeutics
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
6 months ago - By: Zacks Investment Research
- Mentions:
LXRX
AMRN
KURA
KURA Stock Rises More Than 15% This Past Week: Here's Why
6 months ago - By: Zacks Investment Research
- Mentions:
LXRX
TPST
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
6 months ago - By: Chemomab Therapeutics
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
6 months ago - By: Zacks Investment Research
- Mentions:
MRK
LXRX
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
6 months ago - By: Zacks Investment Research
- Mentions:
REGN
LXRX
NTLA
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
6 months ago - By: Zacks Investment Research
- Mentions:
LXRX
AMRN
CADL
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
6 months ago - By: Zacks Investment Research
- Mentions:
LXRX
AMRN
RCKT
RCKT Stock Tanks on Patient Death in Danon Disease Study
6 months ago - By: Zacks Investment Research
- Mentions:
TEVA
LXRX
AMRN
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate
7 months ago - By: Chemomab Therapeutics
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
7 months ago - By: Chemomab Therapeutics
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
7 months ago - By: Chemomab Therapeutics
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
7 months ago - By: Chemomab Therapeutics
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
7 months ago - By: Chemomab Therapeutics
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
8 months ago - By: Chemomab Therapeutics
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
8 months ago - By: Chemomab Therapeutics
Chemomab Announces New Medical and Clinical Appointments
8 months ago - By: Benzinga
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease
8 months ago - By: Chemomab Therapeutics
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
8 months ago - By: Chemomab Therapeutics
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
Please enable JavaScript to continue using this application.